These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30858393)

  • 1. Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects.
    Herman S; Niemelä V; Emami Khoonsari P; Sundblom J; Burman J; Landtblom AM; Spjuth O; Nyholm D; Kultima K
    Sci Rep; 2019 Mar; 9(1):4129. PubMed ID: 30858393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
    Rodrigues FB; Byrne LM; Lowe AJ; Tortelli R; Heins M; Flik G; Johnson EB; De Vita E; Scahill RI; Giorgini F; Wild EJ
    J Neurochem; 2021 Jul; 158(2):539-553. PubMed ID: 33797782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
    Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
    J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
    Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
    Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
    Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
    J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
    Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
    PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
    Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S
    J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
    Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
    Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.
    Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.
    Christodoulou CC; Zachariou M; Tomazou M; Karatzas E; Demetriou CA; Zamba-Papanicolaou E; Spyrou GM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional subcortical shape analysis in premanifest Huntington's disease.
    Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
    Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
    Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
    van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
    Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ
    Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.
    Niemelä V; Burman J; Blennow K; Zetterberg H; Larsson A; Sundblom J
    PLoS One; 2018; 13(2):e0193492. PubMed ID: 29474427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Metabolic Study of Huntington's Disease.
    Nambron R; Silajdžić E; Kalliolia E; Ottolenghi C; Hindmarsh P; Hill NR; Costelloe SJ; Martin NG; Positano V; Watt HC; Frost C; Björkqvist M; Warner TT
    PLoS One; 2016; 11(1):e0146480. PubMed ID: 26744893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.